American Century Companies Inc. Sells 49,942 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

American Century Companies Inc. lessened its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 83.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,124 shares of the company’s stock after selling 49,942 shares during the quarter. American Century Companies Inc.’s holdings in Nurix Therapeutics were worth $211,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Nurix Therapeutics in the first quarter worth $123,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Nurix Therapeutics by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after purchasing an additional 3,793 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Nurix Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares during the last quarter. Finally, Arizona State Retirement System acquired a new position in Nurix Therapeutics in the second quarter valued at $295,000.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the sale, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at approximately $1,126,080.93. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider Christine Ring sold 5,760 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total transaction of $128,044.80. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at $546,680.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Houte Hans Van sold 2,490 shares of the stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $51,468.30. Following the transaction, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at $1,126,080.93. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,815 shares of company stock valued at $1,424,931. Corporate insiders own 7.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on NRIX. Barclays boosted their target price on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Robert W. Baird started coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 price objective on the stock. Truist Financial started coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. upped their price objective on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Finally, Oppenheimer upped their price objective on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $27.00.

Nurix Therapeutics Price Performance

NRIX opened at $22.20 on Friday. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $26.31. The firm has a market capitalization of $1.09 billion, a PE ratio of -7.60 and a beta of 2.22. The company’s 50-day moving average is $23.18 and its 200 day moving average is $18.89.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.09 million during the quarter, compared to the consensus estimate of $19.35 million. As a group, analysts expect that Nurix Therapeutics, Inc. will post -2.95 EPS for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.